Special Issue

Strategies for Addressing Vaccine Hesitancy

Message from the Guest Editor

Vaccine hesitancy, or the delay in accepting or refusing vaccines despite the availability of vaccination services, is a significant contributor to health disparities. Vaccine hesitancy is often caused by misinformation and disinformation, especially among medically underserved populations and those with low levels of health literacy. Vaccine awareness and education are important. Combating misinformation; supporting health literacy; vaccine access; vaccine champions for training, education, and advocacy; and innovative learning strategies can surmount vaccine hesitancy. This Special Issue will focus on laboratory and clinical vaccine research, utilization, and immunization strategies to reduce vaccine hesitancy, which may include long-term, cost-effective approaches to reduce vaccinepreventable disease burden. Circumstances within the scope of Vaccines that affect vaccine complacency. convenience, and confidence are of interest.

Guest Editor

Dr. Donald J. Alcendor

Center for AIDS Health Disparities Research, Department of Microbiology, Immunology and Physiology, Meharry Medical College, Nashville, TN 37208, USA

Deadline for manuscript submissions

31 August 2025



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/197894

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

